Jupiter neurosciences, inc. JUNS.US Overview
JUNS AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
JUNS Current Performance
5.69%
Jupiter neurosciences, inc.
-1.83%
Avg of Sector
-0.40%
S&P500
JUNS Key Information
JUNS Revenue by Segments
Browsing restrictions can be lifted for a fee.
JUNS Net Income
Browsing restrictions can be lifted for a fee.
JUNS Cash Flow
Browsing restrictions can be lifted for a fee.
JUNS Profit Margin
Browsing restrictions can be lifted for a fee.
JUNS PE Ratio River
Browsing restrictions can be lifted for a fee.
JUNS Financial Forecast
Browsing restrictions can be lifted for a fee.
JUNS Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
JUNS Profile
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
Price of JUNS
JUNS FAQ
When is JUNS's latest earnings report released?
The most recent financial report for Jupiter neurosciences, inc. (JUNS) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating JUNS's short-term business performance and financial health. For the latest updates on JUNS's earnings releases, visit this page regularly.
How much debt does JUNS have?
As of the end of the reporting period, Jupiter neurosciences, inc. (JUNS) had total debt of 205.5K, with a debt ratio of 0.04. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does JUNS have?
At the end of the period, Jupiter neurosciences, inc. (JUNS) held Total Cash and Cash Equivalents of 2.71M, accounting for 0.55 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is JUNS's EPS continuing to grow?
According to the past four quarterly reports, Jupiter neurosciences, inc. (JUNS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of JUNS?
Jupiter neurosciences, inc. (JUNS)'s Free Cash Flow (FCF) for the period is -1.06M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 1,531.31% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.